Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

GlobeNewswire April 26, 2022

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

GlobeNewswire March 14, 2022

Tarsus to Present at Upcoming Investor Conferences

GlobeNewswire March 9, 2022

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire February 3, 2022

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

GlobeNewswire February 2, 2022

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

GlobeNewswire February 2, 2022

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

GlobeNewswire January 4, 2022

Tarsus to Participate at Upcoming Virtual Investor Conferences

GlobeNewswire November 23, 2021

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

GlobeNewswire November 10, 2021

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

GlobeNewswire November 9, 2021

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

GlobeNewswire November 4, 2021

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

GlobeNewswire November 2, 2021

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

GlobeNewswire August 12, 2021

Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates

GlobeNewswire August 4, 2021

Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021

GlobeNewswire July 24, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

GlobeNewswire July 7, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

GlobeNewswire June 22, 2021

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire June 21, 2021

Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire June 18, 2021

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease

GlobeNewswire June 16, 2021